Compared with some oncology with clear targets, clear mechanisms and diverse methods, the pathogenesis of some diseases in the field of nervous system diseases (CNS) is not clear, and patients have a long time from disease to onset and are difficult to diagnose, which leads to all pharmaceutical companies having nowhere to start and can only verify conjectures through continuous attempts, while some disease trials take a long time to observe, are time-consuming and labor-intensive, and have huge investment costs.
At the beginning of 2018, Pfizer initially suspended R&D projects in the field of neuroscience, including projects for Alzheimer's disease, Parkinson's disease and epilepsy. Six months after abandoning its own research and development in the field of neuroscience, Pfizer Ventures, an investment company of Pfizer, plans to invest $600 million in emerging biotechnology companies, of which the existing funds (1$500 million) is invested in emerging growth neuroscience companies.
yearsIn January, Pfizer and Bain Capital partnered to launch a company focused on developing central nervous system diseasescerevel therapeuticsPfizer provides a portfolio of compounds in various stages of clinical research and several compounds in preclinical development in disease areas including Parkinson's disease, Alzheimer's disease, epilepsy, psychiatric disorders and addictive diseases. At the same time, Pfizer has developed a five-year plan to invest $600 million as venture capital**, of which up to $1$500 million for neuroscience.
Yaorong Cloud Data wwwpharnexcloud.According to COM monitoring: In October 2020, Cerevel Therapeutics went public through a merger with Spac Arya Sciences II initiated by Perceptive, with a market capitalization of about $2.1 billion at the end of 2020 and a total market capitalization of 45 as of November 14, 2023$9 billion. (The time when the article was written was completed is another case of being acquired before it was published).
As a company focused on brain science, Cerevel Therapeutics opens up new options by precisely identifying and locating neural circuits for specific neuroscience diseasesSelectively target only receptor subtypes that are relevant to disease physiology to minimize undesirable off-target effects while maximizing activity;Not only that, complete and partial agonists, antagonists, and allosteric modulators have been designed to precisely fine-tune receptor pharmacology and neural circuit activity without overactivating or overinhibiting the endogenous physiological range.
Product layout
Leveraging its in-depth research into neural circuitry and targeted receptor subtype selectivity, Cerevel Therapeutics is advancing its broad and diverse pipeline of novel neuroscience product candidates.
emraclidineIt's one of a kindm4Selective positive allosteric modulator (pam), which is being developed for psychiatric disorders and Alzheimer's disease psychosis
The Phase 2 clinical trial for psychiatric disorders was two placebo-controlled studies called empower-1 and empower-2, in which emraclidine was studied as a once-daily drug without titration. Empower program data is expected in the second half of 2024, and recruitment for Empower-3 is currently underway for a 52-week open-label security extension trial. To support a potential registration regimen for Emraclidine** psychiatric disorders, Cerevel Therapeutics prioritizes the completion of necessary non-clinical and clinical pharmacology studies in addition to the EMPOWER program.
M4 positive allosteric modulator of muscarinic acetylcholinergic receptors
For emraclidine's Alzheimer's disease psychosis, Cerevel Therapeutics initiated a Phase 1 multiple ascending dose study to evaluate its safety, tolerability, and pharmacokinetics in healthy elderly volunteers aged 65-85 years. Currently, the FDA has granted Emraclidine Fast Track designation for hallucinations and delusions associated with Alzheimer's psychosis.
Yaorong Cloud Data wwwpharnexcloud.com: Basic information on drug research and development
Darigabat is a 2-3-5-selective GABAA receptor PAM that is currently being developed for epilepsy and panic disorder.
Cerevel Therapeutics is conducting a Realize trial and an Adapt trialrealizeThe trial is a clinical trial for focal epilepsyproof-of-concept and the corresponding open-label safety extension trial, with data readouts expected in:Announced in the middle of the year. adaptThe trial is a clinical trial for panic disorderProof-of-concept.
t**apadonIt's one of a kindd1/d5Some agonists, mainly used in Parkinson's disease, are currently in clinical trialsPeriod
T**apadon has the potential to be the first-in-class D1 D5 selective partial agonist for Parkinson's disease, as a single and adjuvant. For Parkinson's disease (tempo-1with) of all three clinical trials of single** (early) and adjuvant (late).and the corresponding open-label extension trial (tempo-4) is ongoing. Expectedtempo-3The data will be available in:Announced in the first half of the yeartempo-1withtempo-2The data will be available in:Announced in the second half of the year.
cvl-871is a kind of work in progressd1/d5Partial agonists for dementia-related apathy. Clinical trials are currently underway for dementia-related apathy2aexploratory research.
In addition to these pilot programs, Cerevel Therapeutics is advancing its early-stage clinical pipeline and discovery programs, which include CVL-354, a selective opioid receptor antagonist (KORA) for major depressive disorder and substance use disordersSelective M4 agonist regimen for ** psychiatric and neurological indications;Selective PDE4 inhibitor (PDE4D-Sparing) program for psychiatric, neuroinflammatory and other diseases.
Financials
From the pharmaceutical finance cloud data wwwpharnexcloud.com learned that Cerevel Therapeutics has been increasing capital investment since its establishment, and the R&D expenses for the whole year of 2022 will be 2$80.3 billion, R&D expenses include $5 million and $18.2 million based on ** compensation expenses, compared to only $1$61.9 billion, the increase in R&D expenses was primarily due to the continued advancement of the Emraclidine, T**Apadon and Darigabat clinical programs, increased investment in early-stage R&D and increased personnel and other infrastructure costs to support the continued growth and development of the R&D pipeline.
Pharmaceutical Finance Cloud Database: Annual Report of the Company.
As ofyearsmonthThe company's R&D expenses for the first three quarters were:billion billion yuan,Total R&D expenses consisted of $6.8 million and $20.3 million of equity-based compensation expense, with the increase in R&D expenses primarily due to the continued advancement of the Emraclidine and T**Apadon projects and an increase in personnel costs, including equity-based compensation. General and administrative expenses for the first three quarters were:$10,000, which included share-based compensation expense of $10.3 million and $23.9 million, compared to the year-ago quarter, the increase in general and administrative expenses was primarily due to higher personnel costs, including equity-based compensation, partially offset by lower expenses related to professional fees.
Compared to the fourth quarter of 2022, Cerevel Therapeutics expects general and administrative expenses to remain relatively stable in 2023, and the company's cash, cash equivalents and valuable** are expected to continue to support operations through 2025.
December 7, 2023Pharmaceutical giant AbbVie announced a definitive agreement to acquire Cerevel Therapeutics and its robust neuroscience pipeline for $45 per share in cash, valued at approximately $8.7 billion, and is expected to close in 2024.
Reference:nmpa/cde
Yaorong Cloud Data wwwpharnexcloud.com
fda/ema/pmda；
Public disclosure of relevant companies (except for marking, the text ** is from the official website of the company);
Wait a minute.